SCHEDULE 13G: Nantahala Capital Management Discloses 6.52% Stake in Third Harmonic Bio, Inc.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 6.52% in Third Harmonic Bio, Inc.'s common stock as of March 31, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating their beneficial ownership in Third Harmonic Bio, Inc.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 2,938,700 shares of Third Harmonic Bio, Inc.'s common stock.
• This ownership represents 6.52% of the total outstanding shares of the class.
• The Reporting Persons hold shared voting power and shared dispositive power over all 2,938,700 shares.
• Nantahala Capital Management, LLC is classified as an Investment Adviser (IA), while Wilmot B. Harkey and Daniel Mack are classified as Control Persons (HC).
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This document is a factual disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of a significant passive ownership stake by an investment firm in a publicly traded biotechnology company. It does not provide specific insights into Third Harmonic Bio, Inc.'s operational performance or strategic direction, but rather reflects an investment decision by Nantahala Capital Management.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional ownership stake may influence investor perception and trading activity, potentially signaling confidence from a notable investment firm.

Key Dates

Keywords

Third Harmonic Bio Inc., Nantahala Capital Management, Wilmot B. Harkey, Daniel Mack, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, SEC Filing